Generated by AI
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, with an emphasis on Friedreich’s ataxia. The company’s core program is nomlabofusp, a protein replacement therapy designed to deliver frataxin inside cells and address the underlying biology of this inherited disorder. Larimar’s work centers on its proprietary intracellular delivery platform, which is intended to support the development of additional therapies for rare conditions caused by missing or deficient proteins. The company operates as a focused research and development organization, advancing clinical programs and related manufacturing, development, and regulatory activities through external partners. Larimar Therapeutics is based in Bala Cynwyd, Pennsylvania, and plays a specialized role in the rare-disease biopharmaceutical market by pursuing targeted treatments for patients with limited therapeutic options.
WebsiteThree Bala Plaza East
Bala Cynwyd, PA, 19004
United States
The latest articles about LRMR.
Summary of Nov 16's posts. Generated by AI.
Summary of Oct 21's posts. Generated by AI.
Summary of Oct 21's posts. Generated by AI.
Investors talking about LRMR also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.